The Antipyretic Efficacy of Oral and Intravenous Paracetamol and Intramuscular Diclofenac in Patients Presenting With Fever.

NCT ID: NCT01891435

Last Updated: 2013-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

434 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized clinical trial to check the antipyretic efficacy of oral and intravenous paracetamol and intramuscular diclofenac sodium in patients presenting with fever to emergency department.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fever Reduction in Temperature

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

oral paracetamol

patients in this arm will receive 1000mg of oral paracetamol

Group Type ACTIVE_COMPARATOR

Oral paracetamol

Intervention Type DRUG

after giving medicine temperature is checked every 30 minutes for 2 hours

Intravenous paracetamol

patients in this arm will receive 1000 mg of intravenous paracetamol

Group Type ACTIVE_COMPARATOR

Intravenous paracetamol

Intervention Type DRUG

after giving medicine temperature is checked every 30 minutes for 2 hours

Intramuscular Diclofenac

patients in this arm will receive 75 mg of intramuscular diclofenac sodium

Group Type ACTIVE_COMPARATOR

Intramuscular diclofenac

Intervention Type DRUG

after giving medicine temperature is checked every 30 minutes for 2 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral paracetamol

after giving medicine temperature is checked every 30 minutes for 2 hours

Intervention Type DRUG

Intravenous paracetamol

after giving medicine temperature is checked every 30 minutes for 2 hours

Intervention Type DRUG

Intramuscular diclofenac

after giving medicine temperature is checked every 30 minutes for 2 hours

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults between the age of 14-75 years with an oral temperature of more than 38.5 C

Exclusion Criteria

* History of allergy to any of the drugs in the study
* Had taken antipyretics within 8 hours
* Renal, hepatic or haematological disorders
* bronchial asthma, peptic ulcer disease, vomiting
* Pregnant or lactating women
Minimum Eligible Age

14 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hamad Medical Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Firjeeth C Paramba

Specialist, Emergency Department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

osama H Mohammed

Role: PRINCIPAL_INVESTIGATOR

Hamad Medical Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hamad medical corporation

Doha, , Qatar

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Qatar

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9070/09

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ibuprofen in Migraine Patients
NCT04533568 COMPLETED PHASE4